scholarly journals A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

2008 ◽  
Vol 14 (4) ◽  
pp. 1111-1115 ◽  
Author(s):  
Elizabeth Fox ◽  
John M. Maris ◽  
Brigitte C. Widemann ◽  
Wendy Goodspeed ◽  
Anne Goodwin ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pediatric Patients ◽  
Tubulin Inhibitor ◽  
Orally Bioavailable

scholarly journals Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

2011 ◽  
Vol 58 (3) ◽  
pp. 372-379 ◽  
Author(s):  
Lisa M. McGregor ◽  
Clinton F. Stewart ◽  
Kristine R. Crews ◽  
Michael Tagen ◽  
Amy Wozniak ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Phase I Study ◽  
Pediatric Patients

Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2080-2080 ◽  
Author(s):  
S. Y. Cho ◽  
P. C. Adamson ◽  
A. E. Hagey ◽  
B. C. Widemann ◽  
J. M. Maris ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Pediatric Patients ◽  
Binding Agent ◽  
Tubulin Binding ◽  
Orally Bioavailable

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10061-10061 ◽  
Author(s):  
Paul James Wood ◽  
Robyn Strong ◽  
Grant A. McArthur ◽  
Michael Michael ◽  
Elizabeth Algar ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pediatric Patients ◽  
Cns Tumors

Results of a phase I study of RX-5902: An orally bioavailable inhibitor of phosphorylated P68, targeting solid tumors.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2554-2554
Author(s):  
S. Gail Eckhardt ◽  
William Larry Gluck ◽  
Martin Gutierrez ◽  
Christine Peterson ◽  
Reza Mazhari ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Orally Bioavailable

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

2006 ◽  
Vol 12 (16) ◽  
pp. 4882-4887 ◽  
Author(s):  
Elizabeth Fox ◽  
John M. Maris ◽  
Brigitte C. Widemann ◽  
Kysa Meek ◽  
Anne Goodwin ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Tubulin Inhibitor ◽  
Orally Bioavailable

A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 9545-9545
Author(s):  
L. M. McGregor ◽  
S. L. Spunt ◽  
D. Ward ◽  
J. Wu ◽  
C. Billups ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pediatric Patients

Phase I Study of Irinotecan in Pediatric Patients With Malignant Solid Tumors

2002 ◽  
Vol 24 (2) ◽  
pp. 94-100 ◽  
Author(s):  
Hideo Mugishima ◽  
Tadashi Matsunaga ◽  
Keiko Yagi ◽  
Keiko Asami ◽  
Jun-ichi Mimaya ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pediatric Patients

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

2018 ◽  
Vol 66 (3) ◽  
pp. e27540 ◽  
Author(s):  
Rebecca J. Deyell ◽  
Bing Wu ◽  
S. Rod Rassekh ◽  
Dongsheng Tu ◽  
Yvan Samson ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pediatric Patients ◽  
Cancer Trials
Sign in / Sign up

Export Citation Format

Share Document